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 2 
ABSTRACT 28 
Background: The aim of this study was to evaluate C-reactive protein(CRP), 29 
globulin and white cell count as predictors of treatment outcome in pulmonary 30 
tuberculosis. 31 
 32 
Methods: An observational study of patients with active pulmonary tuberculosis was 33 
conducted at a tertiary centre. All patients had serum CRP, globulin and white cell 34 
count measured at baseline and two months following commencement of therapy. The 35 
outcome of interest was requirement for extension of therapy beyond 6 months.  36 
 37 
Results: There were 226 patients included in the study. Serum globulin>45 g/L was 38 
the only baseline biomarker evaluated that independently predicted requirement for 39 
therapy extension(OR 3.59(1.79–7.57;p <0.001)). An elevated globulin level that 40 
failed to normalize at 2 months was also associated with increased requirement for 41 
treatment extension(63.9% versus 5.1%;p<0.001) and had low negative likelihood 42 
ratio(0.07) for exclusion of requirement for therapy extension. On multivariable 43 
analysis, an elevated globulin that failed to normalize at 2 months was independently 44 
associated with requirement for therapy extension (OR 6.12(2.23–16.80);p<0.001). 45 
 46 
Conclusions: Serum globulin independently predicts requirement for treatment 47 
extension in pulmonary TB and outperforms CRP and white cell count as a predictive 48 
biomarker. Normalization of globulin at two months following treatment 49 
commencement is associated with low risk of requirement for treatment extension.  50 
 51 
 52 
 3 
INTRODUCTION 53 
 54 
Tuberculosis (TB) represents a major public health concern and a leading cause of 55 
morbidity and mortality worldwide.1 Active pulmonary TB is typically treated with an 56 
intensive phase of four antimicrobial agents for two months and subsequently with 57 
dual agent continuation phase therapy for a further four months. This regimen leads to 58 
complete microbiological and clinical cure in the majority of cases.1, 2 However, in 59 
some patients, routine therapy fails to adequately control and treat disease, leading to 60 
failure of symptomatic improvement, prolonged infectivity and requirement for 61 
extension of therapy.3 The length of anti-tuberculous therapy can have negative 62 
implications for patient adherence and places increased pressure on health care 63 
systems.4  64 
 65 
Early evaluation of the response to anti-tuberculous therapy has the potential to 66 
optimize routine clinical management of the disease and thus lead to improved 67 
outcomes. A biomarker that is predictive of likely response prior to commencement of 68 
therapy or that can be used to monitor subsequent treatment response could be 69 
invaluable to clinicians. Biomarkers measured at baseline could potentially identify 70 
patients with higher bacterial burden and/or enhanced inflammatory response that 71 
require more intensive monitoring and longer therapy regimens than those with more 72 
minimal uncomplicated disease.5 Early treatment markers may allow identification of 73 
patients in whom ineffective therapy has led to uncontrolled bacterial replication and 74 
development of drug resistance.5, 6 Stratification of patients with TB at diagnosis or 75 
early in therapy into those requiring different therapeutic regimens and durations 76 
could improve compliance and treatment outcome and allow health care services to 77 
focus more attention on patients with greater risk of adverse treatment outcomes.7 An 78 
accurate predictive biomarker would also be invaluable in validation of new TB drug 79 
candidates, thereby accelerating development of novel therapies. 80 
 81 
Currently available baseline markers of disease severity include chest radiographic 82 
findings8-10 and sputum smear grade9, 11 and available clinical indicators of treatment 83 
response include symptomatic improvement12, weight gain13, radiographic resolution8 84 
and sputum culture conversion10, 14. However, the results of microbiological tests can 85 
often be delayed and chest radiograph assessment can be difficult to standardize and 86 
 4 
complicated by presence of chronic changes.5, 6 Therefore, a reliable marker than can 87 
be easily measured in blood as an accurate surrogate of treatment success is 88 
particularly desirable.  89 
 90 
A number of immune parameters in blood have been to shown to correlate with extent 91 
of disease and/or treatment response including neopterin15, 16, c-reactive protein17-19 92 
and haematological parameters such as white cell count and erythrocyte sedimentation 93 
rate 20, 21. However, these parameters have only been assessed in small studies at the 94 
onset of disease. Globulins are a collection of proteins that can be readily measured in 95 
the blood. Total globulin levels are routinely measured in serum samples and are non-96 
specifically elevated in response to several inflammatory conditions including active 97 
tuberculosis22. Studies have previously shown that globulin levels in serum correlate 98 
with adverse outcomes from Pneumocystis jiroveci pneumonia23 and lung cancer24. 99 
The value of serum globulin as a predictor of outcome in tuberculosis has not been 100 
formally evaluated previously. 101 
 102 
The aim of this study was to assess the value of measuring serum levels of routine 103 
inflammatory biomarkers globulin, CRP and white cell count at baseline and two 104 
months following therapy commencement for prediction of outcome in patients 105 
treated for active pulmonary tuberculosis. 106 
 107 
 108 
 109 
 110 
 111 
 112 
 113 
 114 
 5 
METHODS 115 
Study population 116 
We conducted an observational study of consecutive adult patients (>16 years) with 117 
active bacteriologically confirmed pulmonary TB commenced on anti-tuberculous 118 
chemotherapy at St. Mary’s Hospital, London between January 2008 and January 119 
2013. The study received local approval. Patients were included if they had sputum or 120 
bronchoalveolar lavage samples that were positive for culture of Mycobacterium 121 
tuberculosis. 122 
Exclusion criteria were: 123 
 Patients who were treated based on clinical likelihood for pulmonary 124 
tuberculosis but without evidence of positive cultures for Mycobacterium 125 
tuberculosis. 126 
 Loss to follow-up or failure to complete therapy. 127 
 128 
Measurement of inflammatory biomarkers in serum 129 
All patients included in the study had measurement of C-reactive protein, white cell 130 
count and total globulin levels in serum samples taken at baseline (prior to initiation 131 
of anti-tuberculous therapy) with repeat measurement undertaken at 2 months 132 
following commencement of therapy. The normal ranges of the assays were: CRP 0-133 
10 mg/L, globulin 19 – 35 g/L, white cell count 4.0 – 11.0 x 109  cells/L 134 
 135 
Microbiological evaluation 136 
Microscopy was performed in all patients who produced sputum or underwent 137 
bronchoscopy with bronchoalveolar lavage (BAL). The density of acid-fast bacilli 138 
(AFB) was graded as scanty, 1, 2 or 3+ according to standard protocols.25 TB culture 139 
was performed by incubation of sputum or BAL samples using the BactecTM MGIT 140 
TM 960 system (BD, New Jersey USA) for up to 6 weeks. 141 
 142 
Radiographic evaluation 143 
As part of the initial diagnostic evaluation, all patients included in the study 144 
underwent standard posteroanterior chest radiograph to assess for signs of active 145 
tuberculosis including nodules, consolidation and cavitation.  146 
 147 
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 148 
Outcome 149 
The outcome of interest was requirement for extension of antituberculous therapy 150 
beyond 6 months. The indications for extension of therapy were left to the discretion 151 
of the treating physician and included one or more of the following factors: persistent 152 
smear or culture positivity; failure of chest radiograph improvement; drug resistance; 153 
persistent symptoms; poor compliance with therapy; presence of extra-pulmonary 154 
disease and drug- induced liver injury. We also conducted a separate analysis to 155 
evaluate the outcome of persistent sputum smear and/or culture positivity (defined as 156 
> 2 months following treatment initiation). 157 
 158 
Statistical analysis 159 
All data were analysed using SPSS version 13.0 for windows (SPSS Inc., Chicago, 160 
Il). The chi-squared test was used to compare categorical variables. The Mann Witney 161 
U test and the Kruskal Wallis test were used to compare continuous variables between 162 
two or multiple groups respectively.  163 
 164 
Sensitivity, specificity, positive and negative predictive values, positive and negative 165 
likelihood ratios and area under the receiver operator characteristic curve were used to 166 
assess the value of serum biomarkers for prediction of outcomes of interest.  167 
 168 
We used multivariable logistic regression to evaluate the association of baseline and 169 
two-month levels of globulin, CRP and white cell count with outcomes of interest. 170 
The following variables were included in the regression model: age>50 years, male 171 
sex, requirement for directly observed therapy (DOT), alcohol excess, HIV, drug 172 
resistance, smear positivity, poor compliance, cavitating disease and multilobar chest 173 
radiograph changes,  174 
 175 
A two tailed p value<0.05 was considered to be statistically significant176 
 7 
RESULTS 177 
There were 226 patients included in the study. Baseline demographics of the study 178 
cohort are summarized in table 1. 179 
 180 
Correlation of pre-therapy globulin levels with microbiological and radiological 181 
disease burden 182 
Measurement of inflammatory biomarkers prior to commencement of anti-tuberculous 183 
therapy identified 175 patients (77.4%) with an elevated serum globulin (>35 g/dL), 184 
155 patients (68.6%) with an elevated serum CRP (>10mg/L) and 28 patients (12.4%) 185 
with an elevated white cell count (>11.0 x 109/L). Figure 1 shows correlation of pre-186 
therapy levels of these biomarkers with microbiological and radiological markers of 187 
disease burden including smear positivity (fig 1 a-c), radiographic lobar involvement 188 
(fig 1d-f) and presence of cavitatory disease (fig 1 g-i).   189 
 190 
Predictive value of pre-therapy serum inflammatory biomarkers for 191 
requirement of therapy extension  192 
The value of pre-therapy serum CRP, globulin and white cell count levels for 193 
prediction of the requirement for extension of anti-tuberculous therapy (>6 months) 194 
was evaluated. eTable 1 shows reasons for therapy extension (supplementary data). 195 
Table 2 shows that increasing levels of serum globulin, CRP and white cell count 196 
were all significantly associated with increased frequency of requirement for therapy 197 
extension.  198 
 199 
The sensitivity, specificity, positive and negative predictive values, positive and 200 
negative likelihood ratios and AUCs for pre-therapy globulin>45 g/L, CRP>50 mg/dL 201 
and White cell count>11 x 109/L with regards to prediction of requirement for therapy 202 
extension were evaluated. All tests had poor to moderate predictive value with 203 
globulin having the highest AUC (0.70, see table 3). 204 
 205 
Multivariable analyses  206 
On multivariable analysis, pre-therapy globulin >45 g/L was independently associated 207 
with requirement for therapy extension OR 3.42 (1.59 – 7.32; p <0.001). Pre-therapy 208 
CRP>50 mg/L and White cell count>11 x 109/L were not independently associated 209 
with therapy extension (see eTable 2). 210 
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 211 
Evaluation of serial inflammatory biomarker measurements for prediction of 212 
treatment outcome in pulmonary tuberculosis  213 
Having investigated the predictive value of pre-therapy levels of inflammatory 214 
biomarkers, we next evaluated whether measurement of repeat biomarker levels at 215 
two months following initiation of therapy could predict treatment outcome. Table 2 216 
shows rates of requirement for therapy extension stratified according to whether or 217 
not the levels of CRP, globulin or white cell count normalized at two-month 218 
measurement. Significantly increased rates of requirement for therapy extension were 219 
observed in patients in whom globulin or CRP failed to normalize by 2 months post 220 
initiation of therapy but no significant association was observed for normalization of 221 
white cell count (see table 2). 222 
 223 
We next formally assessed the predictive value of normalization of globulin, CRP and 224 
white cell count at two-month measurement for identification of persistent smear 225 
and/or culture positivity and requirement for therapy extension. A globulin that 226 
normalized at 2 months had a negative likelihood ratio of 0.07 for excluding 227 
requirement for therapy extension (see table 3), indicating that this represents a 228 
clinically valuable rule-out test26. CRP and white cell count had poor negative 229 
likelihood ratios for excluding requirement for therapy extension.  230 
 231 
Multivariable analysis 232 
On multivariable analysis, an elevated globulin level that failed to normalize by two 233 
months was independently associated with requirement for therapy extension OR 6.13 234 
(2.23–16.8; p<0.001). CRP that failed to normalize was also independently associated 235 
with therapy extension OR 3.0 (1.15 – 7.82; p = 0.025)(see eTable 2). An analysis of 236 
white cell count normalization could not be carried out due to only a small number of 237 
patients having elevated levels at baseline. 238 
 239 
 240 
 241 
 242 
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Sub-group analysis of baseline and serial biomarkers for prediction of treatment 243 
extension associated with persistent smear/culture positivity or failure of 244 
radiographic improvement 245 
 246 
In addition to evaluation of inflammatory biomarkers as predictors of treatment 247 
extension, we also carried out a sub-analysis to evaluate these tests for prediction of  248 
surrogate markers of treatment response, persistent 2-month sputum smear/culture 249 
positivity and failure of radiographic improvement. Increasing pre-therapy levels of 250 
all three biomarkers correlated significantly with increased frequency of therapy 251 
extension associated with failure of radiographic improvement but not with persistent 252 
smear and/or culture positivity (see table 2). Significantly increased rates of persistent 253 
smear and/or culture positivity were observed in patients in whom globulin, CRP or 254 
white cell count did not normalize by 2 months post initiation of therapy. Patients in 255 
whom globulin or CRP did not normalize also had increased rates of therapy 256 
extension due to failure of radiographic improvement (see table 2). Similar to the 257 
outcome of requirement for treatment extension, a globulin that normalized at 2 258 
months also had the lowest negative likelihood ratio for excluding treatment extension 259 
associated with persistent smear or culture positivity or failure of radiographic 260 
improvement (see table 3).   261 
 262 
 263 
 264 
 265 
 266 
 267 
 268 
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DISCUSSION 269 
 270 
In this study we evaluated the predictive value of the routinely measured serum 271 
biomarkers CRP, globulin and white cell count for prediction of treatment outcome in 272 
patients treated for active pulmonary tuberculosis.  We found that baseline pre-273 
therapy levels of all three biomarkers correlated with the extent of radiological and 274 
microbiological disease burden and increasing pre-therapy biomarker levels were 275 
associated with increased frequency of requirement for therapy extension. However, 276 
after correction for other potential confounding variables, globulin>45 g/L was the 277 
only baseline biomarker found to be independently associated with treatment 278 
outcome. 279 
 280 
All of the tests evaluated performed poorly as pre-therapy predictors of the clinically 281 
relevant outcome of requirement for therapy extension with AUC values < 0.7, the 282 
threshold that represents a clinically useful test. This suggests that none of these tests 283 
could be used alone to accurately predict treatment outcome at baseline. Of the three 284 
markers evaluated, pre-therapy globulin had the highest AUC value as a baseline 285 
predictor of outcome. In particular, only 28 patients (12.3%) had an elevated white 286 
cell count prior to commencement of therapy which highlights that it is extremely 287 
unlikely to be clinically useful as a predictive biomarker. This was reflected in a low 288 
AUC value of 0.58. It is perhaps unsurprising that biomarkers were poorly predictive 289 
of length of treatment. This outcome is not solely dependent on mycobacterial burden 290 
or inflammatory response, which would be expected to correlate directly with serum 291 
levels of immune markers such as globulin, but may also be determined by other 292 
unrelated factors such as poor compliance with therapy or complications such as drug-293 
induced liver injury.  294 
 295 
In addition to assessing the value of pre-therapy biomarker levels, we also evaluated 296 
the predictive value of repeat measurement of inflammatory biomarkers at 2 months 297 
following treatment initiation to determine whether failure of normalization of these 298 
markers correlated with requirement for therapy extension. Failure of normalization 299 
of globulin or CRP was independently associated with requirement for therapy 300 
extension. However, globulin had the lowest negative likehood ratio for excluding 301 
requirement for therapy extension. It is recognized that a threshold of likelihood ratio 302 
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<0.1 is indicative of a clinically useful rule-out test.26 The low negative likelihood 303 
ratio of globulin normalization at 2 months suggests it is a good marker of adequate 304 
response to therapy. Our data therefore suggest that measurement of globulin in 305 
patients commenced on anti-tuberculous therapy with subsequent normalization of 306 
this blood test by 2 months is associated with very low rates of requirement for 307 
treatment extension and raise speculation that globulin may thus be a useful adjunct to 308 
clinical judgment in identifying low-risk patients. By contrast, two-month CRP and 309 
white count measurement had high negative likelihood ratios thus suggesting lack of 310 
utility in a clinical setting. 311 
 312 
Our finding that globulin could predict requirement for therapy extension in 313 
tuberculosis raises speculation it could be a useful marker in clinical practice. Serum 314 
globulin is a simple, cheap and widely available blood test. In most centres, all 315 
patients with active TB are routinely reviewed at 2 months to assess treatment 316 
response and decide whether therapy can be altered from intensive to continuation 317 
phase therapy. Therefore, our finding that normalization of globulin levels at two 318 
months can exclude requirement for treatment extension offers a predictive test that 319 
can be rapidly and reliably measured without the need for additional hospital visits. In 320 
combination with other recognized markers of treatment response, including weight 321 
gain13, symptomatic improvement12 and resolution of radiographic changes 8, serum 322 
globulin provides an additional clinical marker of treatment response that can be 323 
easily assessed by clinicians and could aid decisions regarding safe and appropriate 324 
conversion to continuation phase therapy. 325 
 326 
The length of anti-tuberculous therapy is an important endpoint as it may have 327 
negative implications for patient compliance 27. There is historical data suggesting 328 
that patients who respond early to therapy may be safely managed with a shortened 329 
course of antibiotic therapy 28 although this remains controversial and recent studies 330 
have reported worse outcomes for four month regimens 29, 30. A test such as globulin 331 
that could stratify patients into risk groups to guide duration of treatment could 332 
potentially improve compliance, outcomes and treatment related costs. Further studies 333 
are required to determine whether globulin, alone or in combination with other 334 
predictors, could be used in this way. 335 
 336 
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 337 
Total Globulin level reflects a combination of specific proteins including the alpha 338 
globulins (such as alpha-1-antitrypsin and haptoglobulin), transferrin, complement 339 
and immunoglobulins. Previous studies have shown that complement C4 31 and 340 
M.tuberculosis specific immunoglobulins 32, 33 are elevated in serum from patients 341 
with active TB. We did not formally carry out serum protein electrophoresis in our 342 
study to distinguish which sub-components are specifically elevated in patients with 343 
active tuberculosis but data from these previous studies offers a biologically plausible 344 
explanation for our finding that total globulin is elevated in patients with active TB 345 
and correlates with treatment outcomes. Additionally, as our study was observational 346 
in nature, we could not perform all measurements in all patients. The study may also 347 
be limited by sample size, as indicated by wide confidence intervals observed with 348 
some of our analyses.  349 
 350 
In conclusion, we report that measurement of paired serum globulin samples at 351 
baseline and 2 months into therapy can identify patients at lower risk of requirement 352 
for therapy extension. Globulin outperformed the other biomarkers evaluated in our 353 
study. When combined with other clinical measures, globulin may provide clinicians 354 
with a rapid, simple means of identifying lower risk patients. Whether measurement 355 
of globulin could be used to predict other more robust measures of treatment success 356 
such as recurrent disease and TB-related death remains unknown and further studies 357 
in independent populations are now warranted. 358 
 359 
 360 
 361 
 362 
 363 
 364 
 365 
 366 
 367 
 368 
 13 
 369 
 370 
 371 
 372 
 373 
 374 
 375 
 376 
 377 
 378 
 379 
 380 
 381 
 382 
 383 
 384 
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TABLES 
Table 1: Baseline demographics of study population 
Characteristic n (%) or median (IQR) 
Demographics 
Age (median (IQR) 
Male sex 
Born in UK 
Caucasian 
Black African 
Asian 
Other 
 
33 (25.3-49) 
148 (65.5%) 
53 (23.5%) 
55 (24.3%) 
49 (21.7%) 
51 (22.6%) 
71 (31.4%) 
Comorbidities 
Chronic lung disease 
Diabetes mellitus 
Alcohol excess 
HIV 
Other immunosuppression 
Chronic renal failure  
Chronic liver disease 
Smoker 
 
15 (6.6%) 
6 (2.7%) 
11 (4.9%) 
7 (3.1%) 
2 (0.9%) 
2 (0.9%) 
2 (0.9%) 
21 (9.3%) 
Microbiology 
Smear negative 
Smear Grade: 
Scanty AFB 
+ 
++ 
+++ 
 
Persistent smear and/or culture positivity (>60 days) 
Non MDR drug resistance 
Multi drug resistance 
 
115 (50.9%) 
 
32 (14.2%) 
18 (8.0%) 
18 (8.0%) 
43 (19.0%) 
 
20 (8.9%) 
19 (8.4%) 
9 (4.0%) 
Radiology 
Normal chest radiograph 
Cavitating disease 
Multi-lobar changes 
Pleural effusion  
 
35 (15.5%) 
76 (33.6%) 
78 (34.5%) 
31 (13.7%) 
Treatment outcome 
Requirement for extension of therapy (>6 months) 
TB recurrence 
TB-related death 
 
86 (38.1%) 
2 (0.9%) 
2 (0.9%) 
Abbreviations: AFB=Acid fast bacilli; HIV=human immunodeficiency virus; TB = tuberculosis 
 19 
Table 2: Outcomes stratified according to pre-therapy and two month biomarker levels 
  
n 
Requirement for 
therapy extension 
n (%) 
Persistent smear and/or 
culture  positivity  
n(%) 
Failure of radiographic 
improvement 
n(%) 
Pre-therapy Globulin (g/L) 
<35 
36-40 
41-45 
46-50 
>50 
 
p value 
 
Globulin fails to normalize 
by 2 months 
Yes 
No 
 
p value 
 
51 
56 
57 
42 
20 
 
 
 
 
 
97 
78 
 
10 (19.6%) 
17 (30.4%) 
19 (33.3%) 
24 (57.1%) 
16 (80.0%) 
 
<0.001 
 
 
 
72 (74.2%) 
4 (5.1%) 
 
<0.001 
 
4 (7.8%) 
4 (7.1%) 
5 (8.8%) 
4 (9.5%) 
3 (15.0%) 
 
0.88 
 
 
 
12 (12.4%) 
1 (1.3%) 
 
0.007 
 
3 (5.9%) 
4 (7.1%) 
9 (15.8%) 
12 (28.6%) 
9 (45%) 
 
<0.002 
 
 
 
27 (27.8%) 
4 (5.1%) 
 
<0.001 
Pre-therapy CRP (mg/L) 
 
<10 
11-50 
51-100 
100-150 
>150 
 
p value 
 
CRP fails to normalize by 2 
months 
Yes 
No 
 
p value 
 
 
   71 
70 
45 
21 
19 
 
 
 
 
 
42 
113 
 
 
 
14 (19.7%) 
27 (38.6%) 
21 (46.7%) 
14 (66.7%) 
10 (52.6%) 
 
<0.001 
 
 
 
27 (61.4%) 
44 (28.9%) 
 
0.006 
 
 
3 (4.2%) 
5 (7.1%) 
4 (8.9%) 
4 (19.0%) 
3 (15.7%) 
 
0.184 
 
 
 
7 (16.7%) 
4 (3.5%) 
 
0.0095 
 
 
8 (11.3%) 
9 (12.9%) 
7 (15.6%) 
6 (28.6%) 
7 (36.8%) 
 
0.039 
 
 
 
12 (28.6%) 
9 (8.0%)) 
 
0.0037 
Pre-therapy 
White cell count 
(x109/L) 
<4.0 
4-11 
11-14 
>14 
 
p value 
 
White cell count fails to 
normalize 
Yes 
No 
 
p value 
 
 
 
10 
188 
18 
10 
 
 
 
 
 
3 
25 
 
 
 
2 (20%) 
66 (35.1%) 
11 (61.1%) 
7 (70%) 
 
0.015 
 
 
 
3 (100%) 
14 (56%) 
 
0.258 
 
 
 
1 (10.0%) 
14 (7.4%) 
3 (16.7%) 
1 (10.0%) 
 
0.596 
 
 
 
2 (66.7%) 
2 (8.0%) 
 
0.045 
 
 
 
1 (10.0%) 
26 (13.8%) 
6 (33.3%) 
4 (40.0%) 
 
0.029 
 
 
 
3 (100%) 
19 (76.0%) 
 
1.0 
Abbreviations: CRP = C-reactive protein 
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Table 3: Evaluation of pre-therapy and two month biomarker levels for prediction of outcome 
Test Sensitivity Specificity PPV NPV PLR NLR AUC 
PRE-THERAPY BIOMARKER LEVELS  - THERAPY EXTENSION 
Globulin > 45 
g/L 
46.5%  
(35.7-57.6%) 
84.3 % 
(77.2-89.9%) 
64.5 % 
(51.3%-76.4) 
72.0% 
(64.4 –78.7%) 
2.96  
(1.90 -4.62) 
0.63  
(0.51 –0.78) 
0.70  
(0.63–0.77) 
CRP > 50 
mg/L 
52.3% 
(41.3 – 63.2%) 
71.4 %  
(63.2 –78.7%) 
52.9%  
(41.8 –63.9%) 
70.9%  
(62.9 –78.3%) 
1.83  
(1.32 – 2.55) 
0.67  
(0.52-0.85) 
0.67  
(0.60-0.74) 
WCC > 11 
X 109/mL 
12.8%  
(6.3 – 22.3%) 
87.8%  
(81.5 –92.6%) 
35.7%  
(18.6 –55.9%) 
65.7%  
(58.6 – 72.2% 
1.05  
(0.51 – 2.17) 
0.99  
(0.89 –1.10) 
0.58  
(0.50 – 0.66) 
TWO MONTH BIOMARKER LEVELS  
Globulin fails 
to normalize 
Therapy 
extension 
 
Persistent 
smear and/or 
culture 
positivity 
 
Failure of 
radiographic 
improvement 
 
 
 
94.7% 
(87.1-98.7%) 
 
92.3 % 
(64.0–99.8) 
 
 
 
81.7% 
(70.2-96.4) 
 
 
 
74.8% 
(65.0-82.9%) 
 
47.0% 
(39.6-55.5) 
 
 
 
51.4% 
(42.9-59.8) 
 
 
 
74.2 % 
(64.6-82.6%) 
 
12.4% 
(6.6-20.6) 
 
 
 
27.8 % 
(19.2-37.9) 
 
 
 
94.9 % 
(87.-98.6%) 
 
98.7% 
(93.0 – 100.0) 
 
 
 
94.9 % 
(87.4-98.6) 
 
 
 
3.75 
(2.66-5.29) 
 
1.76 
(1.42-2.18) 
 
 
 
1.79 
(1.44-2.22) 
 
 
 
0.07 
(0.03-0.18) 
 
0.16 
(0.02 -1.07) 
 
 
 
0.25 
(0.10-0.64) 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
CRP fails to 
normalize 
Therapy 
extension 
 
Persistent 
smear and/or 
culture 
positivity 
 
Failure of 
radiographic 
involvement 
 
 
38.0% 
(26.8-50.3%) 
 
17.7 % 
(3.8– 43.4%) 
 
 
 
57.1 % 
(34.0 – 78.2) 
 
 
82.1% 
(72.3-89.7%) 
 
100 % 
(71.5-100%) 
 
 
 
75.8 % 
(67.3 – 83.0) 
 
 
64.3 % 
(48.0-78.5%) 
 
100 % 
(29.2-100%) 
 
 
 
28.6 % 
(15.7-44.6) 
 
 
61.1 % 
(51.4-70.1%) 
 
44 % 
(24.4-65.1%) 
 
 
 
91.3% 
(84.6-95.9) 
 
 
2.13 
(1.23-3.68) 
 
-* 
 
 
 
 
2.36 
(1.46-3.83) 
 
 
0.75 
(0.61-0.93) 
 
0.82 
(0.66-1.03) 
 
 
 
0.57 
(0.34-0.94) 
 
 
 
- 
 
 
- 
 
 
 
- 
White cell 
count fails to 
normalize 
 
Therapy 
extension 
 
Delayed 
smear and/or 
culture 
positivity 
 
Failure of 
radiographic 
involvement 
 
 
 
 
17.7 % 
(3.8-43.4) 
 
 
33.3 % 
(0.8-90.6) 
 
 
13.6 % 
(2.9-34.9) 
 
 
 
 
 
100 % 
(71.5-100) 
 
 
92.0 % 
(74.0-99.0) 
 
 
100 % 
(54.1-100.0) 
 
 
 
 
100 % 
(29.2-100) 
 
 
33.3 % 
(0.8-90.6) 
 
 
100 % 
(29.2-100.0) 
 
 
 
 
44.0 % 
(24.7-65.1) 
 
 
92.0 % 
(74.0-99.0) 
 
 
24 % 
(9.4-45,1) 
 
 
 
 
-* 
 
 
 
12.0 
(1.39-103.48) 
 
 
 
n/a 
 
 
 
 
0.82 
(0.66-1.03) 
 
 
0.52 
(0.20-1.40) 
 
 
0.86 
(0.73-1.02) 
 
 
 
 
- 
 
 
 
- 
 
 
- 
 
NLR = negative likelihood ratio; PLR = positive likelihood ratio; NPV = negative predictive value; PPV = positive predictive value 
* Unable to calculate 
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Figure Legend 
 
Figure 1: Correlation between pre-therapy biomarker levels and microbiological 
and radiological markers of disease burden. Box and whisker plot displaying 
showing median globulin, CRP and white cell count levels stratified according to (a-
c) smear grade (d-f) lobar involvement on chest radiograph and (g-i) presence of 
cavitating disease on chest radiograph. Comparison of groups by Kruskal Wallis test 
in (a) and (b) and Mann-Witney U test in (c). Abbreviations: AFB = acid-fast bacilli. 
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